INTRODUCTION
The reduced form of vitamin C, ascorbate (AH), in addition to being essential for various hydroxylation reactions, has a major role as a powerful, water-soluble, non-enzymic antioxidant [1] . AH can reduce a variety of oxidizing species, including alkoxyl and peroxyl radicals, to eliminate harmful free-radical reactions in aqueous compartments within and outside cells [2] . AH also efficiently maintains α-tocopherol (vitamin E) in itro by reducing α-tocopheroxyl radicals [3] . Thus AH effectively protects plasma lipids against peroxidation by reducing both aqueous [4] and lipid-associated radicals [5] . Extracellular reduction and elimination of reactive oxygen species by AH might be important in several diseases such as atherosclerosis, in which lipoprotein lipid peroxidation is thought to be an important early event [6] .
Ascorbyl radical, the one-electron oxidation product of AH, disproportionates to dehydroascorbic acid (DHA) and AH. Increased plasma levels of DHA, the two-electron oxidation product of AH, have been reported in diseases such as diabetes [7] and might be formed under acute inflammatory conditions in which phagocytes become activated and release oxidants [8] . However, in normal subjects, plasma vitamin C is primarily found in its fully reduced, antioxidant form (AH) [9] . Thus it seems that, under normal physiological conditions, effective mechanism(s) exist that eliminate DHA. Whether the formation and subsequent elimination of DHA is coupled to a replenishment of AH remains largely unknown. A number of potential recycling mechanisms for extracellular AH have been described. These include the disproportionation [1] or extracellular reduction [10] of ascorbyl radicals via a transplasma membrane electron transport system [11] , and the recycling of AH by human blood cells Abbreviations used : AH, ascorbate ; DHA, dehydroascorbic acid ; DIDS, 4,4h-di-isothiocyanostilbene-2,2h-disulphonate ; HBSS, Hanks balanced salt solution ; HUVEC, human umbilical-vein endothelial cells ; PBMC, peripheral blood mononuclear cells ; p-CMBS, p-chloromercuribenzylsulphonate ; PMN, polymorphonuclear leucocytes. 1 To whom correspondence should be addressed (e-mail biochemistry!hri.org.au).
thiocyanostilbene-2,2h-disulphonate and isoascorbate. Efflux of AH from cells was temperature-sensitive and saturable with a low affinity (millimolar, intracellular) for AH. In addition to isolated liver cells, perfusion of intact rat and guinea-pig liver with DHA resulted in AH in the circulating perfusate. Our results show that hepatocytes take up and reduce DHA and subsequently release part of the AH formed, probably via a membrane transporter. By converting extracellular DHA to extracellular AH, the liver might contribute to the maintenance of plasma AH, a process that could be important under conditions of oxidative stress.
Key words : antioxidant, liver, metabolism, transport. [12] . Such mechanisms might be important in humans, incapable of synthesizing vitamin C. In addition to the above recycling pathways, the liver might also contribute to extracellular AH. Thus, as the primary tissue for AH formation in mammals that synthesize vitamin C, the liver is likely to contain one or more mechanisms to release AH. In support of this, increased plasma AH levels are found in mice after intravenous injection of bolus DHA, whereas the addition of a comparable amount of DHA to murine whole blood does not alter plasma AH [13] . We hypothesized that the liver, although incapable of vitamin C synthesis in humans, might retain a mechanism that allows AH secretion into plasma, i.e. it performs a (re)absorption function. To test this, we examined various cells for their ability to form AH extracellularly after incubation with DHA. Here we show that hepatocytes have the capacity to release AH in its reduced form, most probably via a membrane protein distinct from the glucose\DHA transporter. . Before use, nanopure water (Millipore Systems, Australia) and buffers were treated with Chelex-100 resin (Bio-Rad, Hercules, CA, U.S.A.) to remove transitionmetal ions, as verified by the AH auto-oxidation method [14] .
MATERIALS AND METHODS

Materials
Cell preparations
HepG2 (human hepatoma) cells were cultured with standard techniques in Dulbecco's modified Eagle's medium containing 10 % (v\v) fetal bovine serum (heat-inactivated) and 2 mM -glutamine. Cells were maintained in 12-well plates (Falcon, Lincoln Park, NJ, U.S.A.) in air\CO # (19 : 1) at 37 mC and used at 80 % confluence or more. For some efflux experiments, nonadherent HepG2 cells were utilized : HepG2 cells, maintained in T150 cm# flasks (Falcon), were harvested by treatment with trypsin and washed once in serum-containing Dulbecco's modified Eagle's medium. Human umbilical-vein endothelial cells (HUVEC) were obtained from fresh tissue [15] , grown to confluence in gelatin-coated 12-well plates and used on the third passage. The human endothelial cell line ECV 304 was maintained in six-well plates in M199 medium containing 10 % (v\v) fetal bovine serum (heat-inactivated). All cultured cells were washed three times in HBSS before experimentation and were devoid of endogenous AH, as described for various cells maintained in minimal medium.
Whole blood was obtained from normal, healthy volunteers. Before the isolation of polymorphonuclear leucocytes (PMN) and peripheral blood mononuclear cells (PBMC), erythrocytes were sedimented with dextran sulphate (500 kDa) and the resulting supernatant was subjected to Percoll gradients to separate PMN and PBMC, as described [16] . Erythrocytes were obtained from whole blood by centrifugation (500 g, 15 min) and washing in HBSS (three times) with removal of the buffy coat between washes. The purity of the different cell populations was determined by staining (DiffQik Stain ; Lab Aids, Sydney, Australia) and detected by light microscopy.
Cellular uptake of DHA and efflux of AH
Both unlabelled and "%C-labelled DHA were freshly prepared, typically as a 1 mM stock solution, before addition to cells in HBSS. Unless noted otherwise, incubations were performed at 37 mC. For adherent cell experiments, DHA was added in 1 or 2 ml of HBSS to cells in twelve-well or six-well plates respectively. Aliquots of the medium were removed at various times and centrifuged (16 000 g, 15 s) ; the supernatant was analysed for AH and DHA by HPLC (see below). For blood cell suspensions, aliquots were removed at various times and centrifuged (300 g, 5 min) to obtain a clear supernatant for analysis. To determine intracellular AH, cells were washed three times in HBSS to remove extracellular AH and DHA. Cells were extracted with ice-cold 90 % (v\v) methanol\1 mM EDTA followed by centrifugation (16 000 g, 2 min), as described [17] . The clear supernatant was removed and stored on solid CO # for less than 8 h before analysis. For some experiments, both DHA uptake and AH efflux by HepG2 cells were performed in Na + -deficient medium. In such studies, HBSS was replaced with 50 mM potassium phosphate buffer, pH 7.4, containing 5 mM -glucose and 140 mM choline chloride.
For characterization of DHA uptake and AH efflux in HepG2 cells, cells harvested by trypsin were washed and incubated with ["%C]DHA at 37 mC. For ["%C]DHA uptake, aliquots (100 µl) of the cell suspension were removed at various times and placed in an Eppendorf tube over 150 µl of a phthalate oil mixture (density 1.03 g\ml), prepared by combining dibutylphthalate and phthalic acid bis-(2-ethylhexylester) (1 : 1, v\v). Uptake was stopped by centrifugation (16 000 g, 15 s) to separate the extracellular medium (aqueous layer above the oil layer) from the pelleted cells, as described [18] . For efflux assays, aliquots of cells (0.5-1 ml) were removed at various times, the cells were washed once in 10 vol HBSS to remove residual DHA and AH, then resuspended in HBSS to the original volume and incubated further. Aliquots (100 µl) were removed at various times and laid over the phthalate oil as described for the uptake assays, followed by centrifugation to halt efflux. Radiolabel in the aqueous layer was measured by mixing 50 µl with 5 ml of Ultima Gold scintillant followed by liquid-scintillation counting.
The total pellet volume was determined by mixing $H # O with cells before centrifugation. To measure contaminating extracellular radiolabel, ["%C]sucrose was added before centrifugation and the radiolabel was extracted as follows. Triton X-100 [1 % (w\v), 0. 
Determination of DHA and AH by HPLC
Unlabelled DHA was determined indirectly by chemical reduction to AH. Freshly prepared DHA (approx. 100 µM, 100 µl in HBSS) was added to 1 % (w\v) homocysteine (25 µl) and incubated at room temperature for 30 min followed by the electrochemical detection of AH as described [19] . For ["%C]AH and ["%C]DHA detection, this HPLC system was combined with UV (265 nm) and a Flo-One\Beta A-100 radiometric detector (Packard Instruments) containing a 1.5 ml flow cell. The ratio of scintillant (Ultima-Flow M) to mobile-phase flow was 4. AH concentrations were determined by a comparison of peak areas with those of authentic standards.
Liver perfusion experiments
Liver perfusions were performed by the method of [20] except that perfusion in a recirculating mode was used. Male rats (250 g, Wistar) and guinea-pigs (330 g) were used for these studies. The flow rate (35 ml\min for both species) was set so that one pass of the perfusate through the liver and tubing was completed in 1 min. ["%C]DHA was prepared freshly by bromine oxidation of ["%C]AH in nanopure, Chelex-treated water. In brief, bromine (8 µl, 1 : 8 (v\v) in nanopure water) was added to 3.3 mM ["%C]AH (in 350 µl). This solution was mixed thoroughly, excess bromine was removed by nitrogen purging, then the solution was diluted immediately in the perfusate buffer (35 ml, Krebs-Henseleit buffer containing 5 mM -glucose, pH 7.4, 37 mC) to yield a final concentration of 20-40 µM ["%C]DHA. Samples of the circulating perfusate (200 µl) were collected at various times (0-30 min) and fresh perfusate buffer (37 mC, devoid of any additives) was added to maintain a constant volume. The dilution effect was accounted for in the results. The perfusate samples were frozen immediately on solid CO # then maintained at k80 mC (for not more than 24 h) until analysed by HPLC with on-line radiometric detection (see above).
Transplasma membrane electron transport activity
Transplasma membrane electron transport activity in cells was assessed by the reduction of ferricyanide to ferrocyanide ; ferrocyanide was determined by the method of Avron nd Shavit [21] . In brief, non-adherent HepG2 cells (at least 3i10' cells) were incubated in 1 ml of HBSS containing 0.4 mM ferricyanide at 37 mC. After 30 min, cells were pelleted by centrifugation (16 000 g, 1 min). The resulting supernatant (0.7 ml) was then mixed with 0.1 ml of 3 M sodium acetate (pH 6.5), 0.1 ml of 0.2 M citric acid, 0.05 ml of 3.3 mM FeCl $ (in 0.1 M acetic acid) and 0.05 ml of 1 % (w\v) 1,10-phenanthroline (in ethanol). The solution was incubated at 25 mC for 5 min for full colour development. Ferrocyanide was quantified spectrophotometrically from a molar absorption coefficient (ε &"! ) of 10 500 M −" :cm −" [21] .
RESULTS
In contrast with the millimolar intracellular concentration of AH in freshly isolated hepatocytes, HepG2 cells cultured under standard conditions did not contain endogenous AH. We first examined whether HepG2 cells accumulated and reduced DHA and whether part of the resulting AH was subsequently released into the extracellular space. As shown previously for other cell types (see, for example, [13, [22] [23] [24] ), incubation of adherent HepG2 cells in itro with 80 µM DHA at 37 mC resulted in detectable intracellular AH. The concentration of AH increased time-dependently to 5 nmol\10' cells over 1 h, concurrently with a decrease in the concentration of DHA in the extracellular medium ( Figure 1A ). HepG2 cells incubated with DHA also released significant amounts of AH to the extracellular medium. Up to 6 µM AH was released in 1 h, corresponding to approx. 8 % of the DHA added and representing approx. 50 % of the total vitamin C present both intracellularly and extracellularly at 1 h. In contrast, AH was not observed in the medium of control cells incubated in HBSS in the absence of DHA ( Figure 1B ) or during incubation of DHA in the absence of cells (results not shown). Cellular permeability did not change during the time course, as judged by Trypan Blue exclusion, the absence of detectable lactate dehydrogenase in the medium and a lack of ["%C]sucrose uptake by cells (results not shown).
Previous studies on the uptake of extracellular DHA and its subsequent intracellular conversion to AH have commonly used erythrocytes [13, [22] [23] [24] . It has been suggested that erythrocytes release AH [22] ; however, the detection of AH efflux from erythrocytes resuspended at 37 mC in HBSS was hampered by haemoglobin leakage (results not shown), as this gives rise to inadvertent oxidation of AH during sample preparation [25] . When incubated in homologous plasma at 37 mC, freshly isolated whole blood cells owhite cells and erythrocytes, [4.3p2.7(S.D.)]i10* cells\mlq released approx. 5 µM (n l 4) of their endogenous AH per hour. In contrast, HepG2 cells released AH at a more than 1000-fold greater rate than whole blood cells (Table 1) , when compared on a cellular basis.
To determine further whether cells found in human whole blood other than erythrocytes might release intracellular AH, we incubated isolated PMN and PBMC, as well as primary (HUVEC) endothelial cells and the endothelial cell line ECV304, with DHA. When compared with HepG2 cells, these cell types released significantly less AH into the surrounding medium, although all cells accumulated AH after incubation with DHA ( Table 1 ). The apparently high capacity of HepG2 cells to release AH compared with the other cell types could not be explained by a large variation in cell volumes (see Table 1 legend). Although AH accumulation was largest in ECV304 cells, these cells released significantly less AH than HepG2 cells. ECV304 cells did, however, seem to release greater amounts of AH than the corresponding primary cells, HUVEC. The reasons for these differences are not clear at present although it remains possible that glucose and vitamin C transport might be inherently different in the two cell types and\or potential differences exist in their ability to reduce intracellular DHA. AH was stable in HBSS in the presence of all cells for at least 4 h at 37 mC, demonstrating that the absence of extracellular AH was not due to its autooxidation. In addition, all cells (except erythrocytes in buffer alone), remained viable (at least 95 %) for up to 3 h at 37 mC in the presence of 50 µM DHA in HBSS as judged by Trypan Blue exclusion (results not shown).
As liver cells released most AH, HepG2 cells were used for further studies of the putative efflux mechanism involved. We first explored the possibility that extracellular AH was produced by extracellular reduction of DHA or ascorbyl radical. For this, non-adherent HepG2 cells were incubated with ["%C]DHA in the presence or absence of cytochalasin B, a potent inhibitor of glucose [26] and DHA transport in mammalian cells (Figure 2 ). Extracellular ["%C]DHA was transported rapidly into HepG2 cells in the absence of cytochalasin B (Figure 2A ) and significant amounts of ["%C]AH accumulated intracellularly ( Figure 2B ). In Figure 2B ) and correspondingly larger amounts of ["%C]DHA remained present extracellularly ( Figure 2A ). This suggested an effective blockage of DHA uptake by cytochalasin B. Concomitantly with this, the presence of cytochalasin B also strongly inhibited the accumulation of AH outside HepG2 cells ( Figure 2C ), suggesting that, at least under the experimental conditions used, significant extracellular reduction of DHA to AH by HepG2 cells did not take place. At pH 7.4, DHA is unstable at 37 mC and in the absence of cellular uptake (i.e. in the presence of cytochalasin B) it degraded extracellularly to an unknown, single product that was not taken up by HepG2 cells and accounted for the apparent loss of stoichiometry in Figure 2 (D). Although the above results suggest that DHA uptake was required for extracellular AH accumulation, the possibility nevertheless remained that cytochalasin B disrupted the transplasma membrane electron transport system [11] that might transduce extracellular reduction. The activity of transplasma membrane electron transport in HepG2 cells was therefore determined by the rate of ferricyanide reduction, as described previously [11] . In contrast with its effects on DHA uptake, cytochalasin B had no effect on extracellular ferricyanide reduction by HepG2 cells (Table 2) , as has been demonstrated for HL-60 cells [27] and erythrocytes [28] .
Together the above experiments established that liver cells were capable of releasing AH. To exclude the possibility that this was due to an inherent property of immortal cell lines and also to relate the observations in itro to physiology, we performed liver perfusion experiments in situ with rat and guinea-pig livers. In contrast with rats, guinea-pigs (and humans) are unable to synthesize AH de no o. ["%C]DHA (43 µM) added to the buffer perfusing rat liver disappeared rapidly ( Figure 3A ). After this, 2.3 µM ["%C]AH, corresponding to approx. 5 % of the added ["%C]DHA, appeared in the perfusate over 30 min ( Figure 3A) . In addition to radiolabelled AH, comparably larger amounts of unlabelled, endogenous AH were secreted from rat liver when perfused with buffer in the presence or absence of ["%C]DHA ( Figure 3B ). Similarly to the rat, guinea-pig liver released ["%C]AH ( Figure 4A ) and considerable amounts of unlabelled AH ( Figure 4B ) after perfusion with 19 µM ["%C]DHA. These results demonstrate that AH release from the liver can be observed, independently of whether the animal is capable of vitamin C synthesis. Bile samples obtained from each species contained neither AH nor radioactivity (results not shown).
The transport of DHA into, and AH efflux from, HepG2 cells was characterized further. Uptake and release of the two forms of vitamin C were found to be differentially affected by various reagents (Table 3) , suggesting two separate transport mechanisms. In agreement with previous studies [29] , DHA uptake was inhibited by reagents known to block mammalian glucose transport, including cytochalasin B and phloretin (Table  3) . Importantly, cytochalasin D did not affect transport, precluding a non-specific interaction of the cytochalasins with the cell cytoskeleton to affect DHA uptake or AH release. NEthylmaleimide and p-CMBS strongly inhibited DHA transport, probably by reacting with sensitive thiols of the glucose transporter (Table 3) . Inhibition of DHA uptake was determined as a decrease in intracellular AH accumulation compared with control cells ; this method might inadvertently measure an effect on intracellular DHA reduction. However, none of the reagents used inhibited DHA reduction by HepG2 cell lysates (results not shown).
In contrast with DHA uptake, cytochalasin B had little effect on AH release from cells (Table 3) . Phloretin significantly inhibited AH efflux, whereas AH release from cells seemed to be relatively insensitive to N-ethylmaleimide (permeable) or p-CMBS (impermeable), both of which blocked DHA transport by more than 95 %. These results suggest that AH efflux probably does not involve sensitive thiol groups and is different from the
Figure 4 AH is released from guinea-pig liver after a bolus of DHA
The experiment was performed as described for rat liver in Figure 3 except that 19p1.5 µM [ 14 C]DHA was added to the perfusion buffer. The symbols are as described in the legend to Figure 3 . Results are means and extents of variation (error bars) for two separate animals. glucose transporter. DIDS, which interacts with anion transporters [30] , inhibited AH release from cells. Dissipation of the plasma membrane Na + gradient by ouabain or deletion of Na +
Table 3 Effect of various reagents on DHA uptake and AH release from HepG2 cells
For DHA uptake studies, various reagents were preincubated with cells (approx. 10 6 in 1 ml of HBSS) for 15 min at 37 mC. DHA (80 µM) was then added and uptake was monitored by analysing the intracellular AH levels at 30 min as described in the Materials and methods section. AH release from cells was performed by preincubating the cells with DHA (80 µM) for 30 min at 37 mC followed by three washes to remove residual DHA and any AH formed extracellularly. Inhibitors were then added to the cells (in 1 ml of HBSS) and extracellular AH was determined after 15 min at 37 mC. Results are representative of meanspS.D., derived from four individual experiments with different cell preparations. Control cells were incubated with DHA for uptake and efflux studies as described above but were not treated with any other reagent. The 100 % values shown represent DHA transport and AH release in control cells. 
Reagent
Figure 5 AH efflux from HepG2 cells is temperature-sensitive
Non-adherent HepG2 cells [(2.5p0.7)i10 6 in 1 ml] were incubated with [ 14 C]DHA (100p15 µM) for 15 min at 37 mC. Cells were then washed three times with cold HBSS, resuspended in two equal portions (2 ml) of cold buffer and incubated further at 37 mC ($) or 4 mC (#). Aliquots (100 µl) were removed at various times and AH efflux was halted by pelleting the cells through an oil layer as described in the Materials and methods section. Extracellular [
14 C]AH in the aqueous layer was determined by liquid-scintillation analysis. Results are meanspS.D. for three individual, duplicate assays.
from the medium had little effect on DHA uptake and AH efflux (Table 3 , and results not shown), suggesting that neither transport process was Na + -dependent. Isoascorbate, the stereoisomer of AH, had little effect on DHA uptake but inhibited AH release (Table 3) . 6-Chloroascorbate, an analogue previously shown to inhibit AH transport effectively [24] , affected only DHA uptake. None of the reagents tested significantly altered the stability of AH at 37 mC in buffer devoid of cells (results not shown).
The differential effect on AH release from HepG2 cells by inhibitors suggested the involvement of a facilitated transporter. To characterize this putative transport mechanism, the temperature dependence of AH efflux by HepG2 cells pretreated with DHA was tested. AH release was significantly lower at 4 mC than at 37 mC ( Figure 5 ), suggesting facilitated, but not energy- dependent (Table 3) , transport into the extracellular medium. In addition, the rate of AH efflux from HepG2 cells containing various intracellular concentrations of AH was saturable with a K m of 2.4 mM (intracellular) and a V max of 0.17 µM AH released\min ( Figure 6 ).
DISCUSSION
This study addressed whether cells present in, or exposed to, plasma vitamin C could facilitate the maintenance of the vitamin in its reduced, antioxidant-active form by the release of cellular AH. HepG2 cells (hepatocytes) released AH after incubation with the two-electron oxidized form of the vitamin, DHA. In contrast, various cells associated with whole blood (PMN, PBMC and endothelial cells) were significantly less effective in maintaining extracellular AH. Further, perfusion studies in situ revealed that livers obtained from both rats and guinea-pigs released AH into the circulating perfusate. In agreement with previous studies [29] , DHA uptake was mediated by glucose transporters in HepG2 cells. However, AH release from HepG2 cells seemed to be mediated by a separate temperature-sensitive mechanism that was susceptible to inhibition by phloretin and DIDS but was not affected by the glucose transport inhibitor cytochalasin B. Together, the results demonstrate that hepatocytes convert extracellular DHA into extracellular AH and that AH efflux probably involves facilitated transport. The results presented here suggest that the liver might be involved in the maintenance of extracellular AH. Our findings, that liver cells and intact liver accommodate a mechanism to export AH, are novel. Although vitamin C synthesis, where it occurs in mammals, is performed in the liver, a transport mechanism that mediates AH efflux from this organ for delivery to other tissues has not been characterized. Despite this it is not unreasonable to suggest that such a mechanism exists and remains even in hepatocytes of non-synthesizing species. Indeed, we were able to confirm that AH efflux from human hepatocytes and intact liver of the rat (synthesizing) or the guinea-pig (non-synthesizing) occurs. Together with (re)absorptive processes, AH efflux from the liver is likely to be important in overall AH homoeostasis in all species. In this context, it might be interesting to test whether liver disease and\or partial hepatectomy adversely affect whole-body vitamin C levels.
In comparison with the liver, the transport of vitamin C in organs important for (re)absorption is well understood (reviewed in [31, 32] ). Thus transport of AH across brush-border membranes in both intestinal and renal epithelia is Na + -dependent, whereas AH efflux across the corresponding basolateral membrane is independent of Na + ions. In agreement with this, the AH efflux described here was also found to be Na + -independent, because ouabain, which dissipates Na + gradients in cells, and the deletion of Na + from the medium by replacement with choline ions (Table  3 , and results not shown), were without effect on AH efflux from HepG2 cells. Our results, and those of others (reviewed in [31, 32] ), suggest that AH uptake and efflux from cells are mediated via distinct membrane transport systems.
At physiological pH, AH is present predominantly as an anion ; there is little evidence that either DHA or AH traverses cell membranes via simple diffusion. As mentioned above, in cells in which AH efflux has been studied (intestinal and renal epithelia), transport has been described as being mediated via a facilitated transporter. Our results also support facilitated AH efflux from HepG2 cells because this process was sensitive to temperature and was differentially inhibited by various reagents, thus showing some degree of specificity. Although AH efflux from HepG2 cells seemed to be facilitated, the transport mechanism involved was clearly distinguished from mammalian glucose\DHA transport (Table 3 ). The inhibition of AH efflux from HepG2 cells by phloretin and DIDS agrees with previous studies on other cells [33] [34] [35] [36] . The putative AH transport mechanism might have characteristics in common with DIDS-sensitive anion channels but further work is required to support this hypothesis. Similarly to the AH efflux described here, hepatocytes can also release glucose via a cytochalasin-B-insensitive temperature-dependent pathway [37] , although this transporter has not been characterized further.
Further evidence for facilitated AH efflux included saturable rate constants. The affinity of the putative transporter for AH seemed to be low and in the millimolar range. Various cells contain a low-affinity AH transporter (K m 2-7 mM) that has been primarily described for AH influx [36, [38] [39] [40] . In addition, cells accumulate millimolar levels of AH intracellularly [23, 38, 41] . Thus an intracellular millimolar K m for AH efflux in hepatocytes might be physiologically relevant.
In comparison with AH efflux from cells, more is known of DHA uptake into cells, largely because DHA formation outside cells is expected and has been shown to occur under conditions of oxidative stress [8] . DHA uptake into cells is accompanied by intracellular reduction to AH catalysed by one or more intracellular proteins [42, 43] . However, despite this rapid and complete intracellular reduction of DHA in a wide variety of cells, including whole blood cells, AH release from these cells has not been reported. Furthermore, frog oocytes transfected with the mammalian glucose (GLUT 1) transporter isoform take up DHA but specifically fail to release intracellularly reduced AH [29] . Thus cells need to be specifically equipped with a mechanism to mediate AH efflux, a process that seems to be biochemically and biophysically distinct from the transport of DHA (oxidized vitamin C).
The concentration of AH in human plasma is probably determined by several factors, including dietary intake, renal loss, absorption by tissues and redox processes. Uptake of DHA and subsequent release of AH by the liver could be important under conditions of oxidative stress. Consistent with this is the observation that reactive oxygen species can activate glucose transport in cells [44] . Increased glucose transport could represent an adaptive antioxidant response that bolsters energy levels (and cellular reducing agents including NADH\NADPH) as well as enhancing the recycling of extracellular AH. Further, as mentioned above, AH recycling is stimulated by oxidative stress, suggesting that various cells have a large capacity to handle oxidized vitamin C.
It has been suggested that erythrocytes, carrying up to 30 % of the total whole-blood vitamin C, are responsible for maintaining AH and enhancing the antioxidant reserve of human whole blood [12] . Several studies [12, 27, 45] have suggested that AH and NADH act as intracellular electron donors for transplasma membrane electron transport systems [11] that transfer electrons to extracellular acceptors and hence might participate in the maintenance of extracellular AH. In addition, electrons might be transferred to plasma membrane monodehydroascorbate reductases, thereby maintaining extracellular AH under oxidative conditions that produce ascorbyl radicals [46] . It is not known whether DHA can accept electrons via such systems to form AH ; however, the results shown here suggest that this is unlikely for the following reasons. First, AH was released from cells after the removal of DHA from the extracellular medium. Secondly, blockage of DHA uptake, but not ferricyanide reduction, significantly decreased extracellular AH concentration. Thirdly, little AH was maintained extracellularly in the presence of DHA and human whole blood cells, although these cells have an equivalent, if not a higher, capacity to reduce ferricyanide than HepG2 cells [47] .
In conclusion, this study has identified that hepatic AH can be released. In intact liver (Figures 3 and 4) this release does not require, though it is enhanced by, DHA uptake, suggesting that it might boost the extracellular antioxidant reserve of vitamin C. We propose that AH release by the liver is a hitherto unrecognized mechanism in vitamin C homoeostasis. Together with adequate dietary intake, renal absorption and ascorbyl radical\DHA reducing systems, the release of AH by the liver might be important in the bioavailability of AH in plasma in its reduced form for cellular and antioxidant roles.
